What is Zacks Research's Forecast for NKTR FY2025 Earnings?

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Zacks Research issued their FY2025 earnings per share estimates for Nektar Therapeutics in a research note issued on Monday, June 30th. Zacks Research analyst K. Das expects that the biopharmaceutical company will earn ($8.76) per share for the year. The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.72) per share.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($3.30) earnings per share for the quarter, missing analysts' consensus estimates of ($2.70) by ($0.60). The business had revenue of $10.46 million for the quarter, compared to analysts' expectations of $15.61 million. Nektar Therapeutics had a negative return on equity of 329.54% and a negative net margin of 152.49%. During the same quarter in the prior year, the company posted ($2.70) earnings per share.

NKTR has been the topic of a number of other reports. Oppenheimer raised shares of Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $90.00 price target on the stock in a research note on Friday, March 14th. HC Wainwright boosted their target price on Nektar Therapeutics to $120.00 and gave the company a "buy" rating in a research report on Tuesday, June 24th. BTIG Research upped their price target on Nektar Therapeutics from $60.00 to $100.00 and gave the stock a "buy" rating in a research note on Tuesday, June 24th. Wall Street Zen cut Nektar Therapeutics from a "hold" rating to a "sell" rating in a research note on Wednesday, May 14th. Finally, Jefferies Financial Group raised Nektar Therapeutics from a "hold" rating to a "buy" rating and increased their target price for the stock from $15.00 to $30.00 in a research note on Friday, April 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $84.17.

Nektar Therapeutics Trading Down 3.4%

NASDAQ NKTR traded down $0.88 during trading hours on Thursday, reaching $24.65. The company had a trading volume of 994,109 shares, compared to its average volume of 477,427. The stock has a market capitalization of $305.91 million, a P/E ratio of -2.57 and a beta of 0.94. The stock has a 50-day moving average of $12.97 and a 200 day moving average of $12.54. Nektar Therapeutics has a 1-year low of $6.48 and a 1-year high of $37.38.

Hedge Funds Weigh In On Nektar Therapeutics

Institutional investors have recently modified their holdings of the business. Two Sigma Securities LLC raised its stake in shares of Nektar Therapeutics by 56.3% in the fourth quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 9,958 shares in the last quarter. Harvest Investment Services LLC purchased a new stake in Nektar Therapeutics during the 4th quarter worth about $27,000. US Asset Management LLC acquired a new stake in Nektar Therapeutics in the 4th quarter valued at about $31,000. Algert Global LLC purchased a new position in shares of Nektar Therapeutics in the 1st quarter valued at about $33,000. Finally, US Bancorp DE boosted its stake in shares of Nektar Therapeutics by 257.8% in the 1st quarter. US Bancorp DE now owns 50,085 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 36,085 shares during the period. Institutional investors and hedge funds own 75.88% of the company's stock.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.